vs

Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and CALIFORNIA WATER SERVICE GROUP (CWT). Click either name above to swap in a different company.

CALIFORNIA WATER SERVICE GROUP is the larger business by last-quarter revenue ($210.7M vs $156.4M, roughly 1.3× BIOCRYST PHARMACEUTICALS INC). On growth, BIOCRYST PHARMACEUTICALS INC posted the faster year-over-year revenue change (7.5% vs -3.3%). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (19.6% CAGR vs 16.6%).

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

California Water Service Group (CWSG) is an American public utility company providing drinking water and wastewater services. It is the third-largest investor-owned publicly traded water utility in the United States, serving roughly two million people through its subsidiary companies in California, Hawaii, New Mexico and Washington. CWSG was formed in 1997 as a new holding company for California Water Service to expand into other states regulated by their own public utilities commissions, and...

BCRX vs CWT — Head-to-Head

Bigger by revenue
CWT
CWT
1.3× larger
CWT
$210.7M
$156.4M
BCRX
Growing faster (revenue YoY)
BCRX
BCRX
+10.8% gap
BCRX
7.5%
-3.3%
CWT
Faster 2-yr revenue CAGR
BCRX
BCRX
Annualised
BCRX
19.6%
16.6%
CWT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BCRX
BCRX
CWT
CWT
Revenue
$156.4M
$210.7M
Net Profit
$11.5M
Gross Margin
Operating Margin
13.6%
12.2%
Net Margin
5.4%
Revenue YoY
7.5%
-3.3%
Net Profit YoY
-41.0%
EPS (diluted)
$0.00
$0.19

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCRX
BCRX
CWT
CWT
Q1 26
$156.4M
Q4 25
$406.6M
$210.7M
Q3 25
$159.4M
$314.1M
Q2 25
$163.4M
$256.2M
Q1 25
$145.5M
$182.7M
Q4 24
$131.5M
$217.8M
Q3 24
$117.1M
$306.2M
Q2 24
$109.3M
$226.7M
Net Profit
BCRX
BCRX
CWT
CWT
Q1 26
Q4 25
$245.8M
$11.5M
Q3 25
$12.9M
$61.2M
Q2 25
$5.1M
$42.2M
Q1 25
$32.0K
$13.3M
Q4 24
$-26.8M
$19.5M
Q3 24
$-14.0M
$60.7M
Q2 24
$-12.7M
$40.6M
Gross Margin
BCRX
BCRX
CWT
CWT
Q1 26
Q4 25
97.7%
Q3 25
98.6%
Q2 25
98.3%
Q1 25
96.9%
Q4 24
95.4%
Q3 24
97.3%
Q2 24
98.4%
Operating Margin
BCRX
BCRX
CWT
CWT
Q1 26
13.6%
Q4 25
64.0%
12.2%
Q3 25
18.6%
22.5%
Q2 25
18.2%
20.2%
Q1 25
14.6%
12.2%
Q4 24
-3.4%
14.8%
Q3 24
6.6%
21.8%
Q2 24
8.0%
21.2%
Net Margin
BCRX
BCRX
CWT
CWT
Q1 26
Q4 25
60.5%
5.4%
Q3 25
8.1%
19.5%
Q2 25
3.1%
16.5%
Q1 25
0.0%
7.3%
Q4 24
-20.4%
8.9%
Q3 24
-12.0%
19.8%
Q2 24
-11.6%
17.9%
EPS (diluted)
BCRX
BCRX
CWT
CWT
Q1 26
$0.00
Q4 25
$1.13
$0.19
Q3 25
$0.06
$1.03
Q2 25
$0.02
$0.71
Q1 25
$0.00
$0.22
Q4 24
$-0.13
$0.31
Q3 24
$-0.07
$1.03
Q2 24
$-0.06
$0.70

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCRX
BCRX
CWT
CWT
Cash + ST InvestmentsLiquidity on hand
$259.0M
$51.8M
Total DebtLower is stronger
$1.5B
Stockholders' EquityBook value
$1.7B
Total Assets
$465.1M
$5.7B
Debt / EquityLower = less leverage
0.87×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCRX
BCRX
CWT
CWT
Q1 26
$259.0M
Q4 25
$274.7M
$51.8M
Q3 25
$212.9M
$76.0M
Q2 25
$260.0M
$50.5M
Q1 25
$295.1M
$44.5M
Q4 24
$320.9M
$50.1M
Q3 24
$96.8M
$59.6M
Q2 24
$78.4M
$37.3M
Total Debt
BCRX
BCRX
CWT
CWT
Q1 26
Q4 25
$1.5B
Q3 25
$1.1B
Q2 25
$1.1B
Q1 25
$1.1B
Q4 24
$1.1B
Q3 24
Q2 24
Stockholders' Equity
BCRX
BCRX
CWT
CWT
Q1 26
Q4 25
$-119.2M
$1.7B
Q3 25
$-387.9M
$1.7B
Q2 25
$-421.6M
$1.7B
Q1 25
$-451.9M
$1.6B
Q4 24
$-475.9M
$1.6B
Q3 24
$-468.6M
$1.6B
Q2 24
$-475.6M
$1.5B
Total Assets
BCRX
BCRX
CWT
CWT
Q1 26
$465.1M
Q4 25
$514.2M
$5.7B
Q3 25
$446.4M
$5.5B
Q2 25
$457.2M
$5.4B
Q1 25
$480.0M
$5.3B
Q4 24
$490.4M
$5.2B
Q3 24
$491.3M
$5.0B
Q2 24
$472.4M
$4.9B
Debt / Equity
BCRX
BCRX
CWT
CWT
Q1 26
Q4 25
0.87×
Q3 25
0.65×
Q2 25
0.67×
Q1 25
0.68×
Q4 24
0.67×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCRX
BCRX
CWT
CWT
Operating Cash FlowLast quarter
$47.9M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
4.17×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCRX
BCRX
CWT
CWT
Q1 26
Q4 25
$292.0M
$47.9M
Q3 25
$41.6M
$167.3M
Q2 25
$41.3M
$48.9M
Q1 25
$-27.5M
$38.4M
Q4 24
$-5.2M
$68.1M
Q3 24
$8.2M
$101.8M
Q2 24
$-1.4M
$94.4M
Free Cash Flow
BCRX
BCRX
CWT
CWT
Q1 26
Q4 25
$291.2M
Q3 25
$40.3M
Q2 25
$41.1M
Q1 25
$-27.7M
Q4 24
$-5.9M
Q3 24
$8.2M
Q2 24
$-1.5M
FCF Margin
BCRX
BCRX
CWT
CWT
Q1 26
Q4 25
71.6%
Q3 25
25.3%
Q2 25
25.2%
Q1 25
-19.0%
Q4 24
-4.5%
Q3 24
7.0%
Q2 24
-1.4%
Capex Intensity
BCRX
BCRX
CWT
CWT
Q1 26
Q4 25
0.2%
Q3 25
0.8%
Q2 25
0.1%
Q1 25
0.1%
Q4 24
0.5%
Q3 24
0.1%
Q2 24
0.1%
Cash Conversion
BCRX
BCRX
CWT
CWT
Q1 26
Q4 25
1.19×
4.17×
Q3 25
3.23×
2.73×
Q2 25
8.12×
1.16×
Q1 25
-859.91×
2.88×
Q4 24
3.50×
Q3 24
1.68×
Q2 24
2.33×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BCRX
BCRX

ORLADEYO$148.3M95%
Other revenues$5.0M3%
License revenue$3.0M2%

CWT
CWT

Residential$133.2M63%
Business$47.7M23%
Public Authorities$13.4M6%
Industrial$6.9M3%
Non Regulated Services$4.8M2%
Other Non Regulated Service$1.2M1%

Related Comparisons